Article Information
vol. 9 no. 445 ra91
PubMed:
Published By:
Print ISSN:
Online ISSN:
History:
- Received November 6, 2015
- Accepted August 24, 2016
- .
Copyright & Usage:
Copyright © 2016, American Association for the Advancement of Science
Research ArticleCANCER TREATMENT
Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML
- Isabel Morgado-Palacin1,*,
- Amanda Day2,*,
- Matilde Murga1,*,
- Vanesa Lafarga1,
- Marta Elena Anton1,
- Anthony Tubbs2,
- Hua-Tang Chen2,
- Aysegul V. Ergen2,
- Rhonda Anderson2,
- Avinash Bhandoola2,
- Kurt G. Pike3,
- Bernard Barlaam3,
- Elaine Cadogan3,
- Xi Wang4,
- Andrew J. Pierce3,
- Chad Hubbard2,
- Scott A. Armstrong4,
- André Nussenzweig2,†, and
- Oscar Fernandez-Capetillo1,5,†
- 1Genomic Instability Group, Spanish National Cancer Research Center, Madrid 28029, Spain.
- 2Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- 3AstraZeneca, Cambridge CB4 0WG, UK.
- 4Human Oncology and Pathogenesis Program and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- 5Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Solna 17165, Sweden.
- ↵†Corresponding author. Email: ofernandez{at}cnio.es (O.F.-C.); nussenza{at}mail.nih.gov (A.N.)
↵* These authors contributed equally to this work.
See allHide authors and affiliations
Science Signaling 13 Sep 2016:
Vol. 9, Issue 445, pp. ra91
DOI: 10.1126/scisignal.aad8243
Vol. 9, Issue 445, pp. ra91
DOI: 10.1126/scisignal.aad8243
Isabel Morgado-Palacin
1Genomic Instability Group, Spanish National Cancer Research Center, Madrid 28029, Spain.
Amanda Day
2Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Matilde Murga
1Genomic Instability Group, Spanish National Cancer Research Center, Madrid 28029, Spain.
Vanesa Lafarga
1Genomic Instability Group, Spanish National Cancer Research Center, Madrid 28029, Spain.
Marta Elena Anton
1Genomic Instability Group, Spanish National Cancer Research Center, Madrid 28029, Spain.
Anthony Tubbs
2Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Hua-Tang Chen
2Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Aysegul V. Ergen
2Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Rhonda Anderson
2Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Avinash Bhandoola
2Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Kurt G. Pike
3AstraZeneca, Cambridge CB4 0WG, UK.
Bernard Barlaam
3AstraZeneca, Cambridge CB4 0WG, UK.
Elaine Cadogan
3AstraZeneca, Cambridge CB4 0WG, UK.
Xi Wang
4Human Oncology and Pathogenesis Program and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Andrew J. Pierce
3AstraZeneca, Cambridge CB4 0WG, UK.
Chad Hubbard
2Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Scott A. Armstrong
4Human Oncology and Pathogenesis Program and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
André Nussenzweig
2Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Oscar Fernandez-Capetillo
1Genomic Instability Group, Spanish National Cancer Research Center, Madrid 28029, Spain.
5Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Solna 17165, Sweden.
